

## Hybrigenics set up an international Clinical Advisory Board

**Paris, 16 November 2015** – Hybrigenics (FR0004153930 - ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases, today announces the first meeting of its newly assembled Clinical Advisory Board (CAB) which took place on November 10<sup>th</sup>, 2015 at its headquarters in Paris. The topics of this meeting were acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

Hybrigenics' CAB is composed of three American and two French clinical experts in hematologic oncology:

- Prof. J. Cortes, Chair of the AML and CML sections, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston,
- Prof. O. Hermine, Chair of the Department of Hematology, Necker Hospital, Paris,
- Prof. M. Mauro, Leader of the Myeloproliferative Diseases Program, Memorial Sloan-Kettering Cancer Center, New York,
- Prof. M. Tallman, Chief of the Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York,
- Prof. A. Thuran, Chair of the Department of Hematology, Kremlin-Bicetre Hospital, France.

Hybrigenics is currently conducting a Phase II clinical study of oral inecalcitol in CML patients in France only. Hybrigenics is also preparing another Phase II clinical trial of oral inecalcitol in elderly or frail AML patients, an indication for which it has received Orphan Drug designation both in Europe and in the United States. This AML study aims at being performed both in France and in the United States. Prof. O. Hermine and Prof. J. Cortes will be the principal investigators in their respective country.

*"The insights of the experts in blood cancers gathered during this clinical advisory board meeting at Hybrigenics are invaluable for the design and the implementation of the upcoming clinical study of inecalcitol in elderly or frail patients suffering from acute myeloid leukemia,"* said Dr. Jean-François Dufour-Lamartinie, Hybrigenics' Chief Medical Officer. *"Their experience and implication will also be extremely useful to shape the future of inecalcitol in the therapeutic area of adult leukemias,"* added Remi Delansorne, Hybrigenics' CEO.

### **About Hybrigenics**

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere<sup>®</sup>, which is the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. A clinical Phase II study of inecalcitol is currently ongoing in chronic myeloid leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes (DUBs) and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. A first milestone has been achieved in a drug discovery program targeting one DUB in oncology.

# HYBRIGENICS

Press Release

Hybrigenics Services ([www.hybrigenics-services.com](http://www.hybrigenics-services.com)) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio ([www.helixio.com](http://www.helixio.com)), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500.

Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

\*\*\*

**HYBRIGENICS is listed on the Alternext market of Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



**Hybrigenics**

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

[investors@hybrigenics.com](mailto:investors@hybrigenics.com)

**NewCap**

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

[hybrigenics@newcap.eu](mailto:hybrigenics@newcap.eu)